Subsequent Event

12 Months Ended

Dec. 31, 2015

Subsequent Events [Abstract]

Subsequent Event

SUBSEQUENT EVENTS

Out-License of ZEVALIN, FOLOTYN, BELEODAQ, and MARQIBO in Canada

On January 8, 2016, we entered into a strategic partnership with Servier Canada, Inc. for the out-licenses of ZEVALIN, FOLOTYN, BELEODAQ, and MARQIBO. We will receive $6 million in upfront payments, development milestone payments if/when achieved, and a high single-digit royalty on their sales of these products.

FDA Approval of EVOMELA

On March 10, 2016, the FDA communicated its approval of our NDA for EVOMELA. Upon receipt of FDA approval, we are contractually obligated to make a $6.0 million milestone payment to Ligand Pharmaceuticals Incorporated within 30 days (see Note 10(b)); accordingly, this payment is due no later than April 9, 2016.